|
Press Releases |
|
 |
|
Wednesday, April 9, 2025 |
|
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis |
SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a novel investigational therapy targeting the IL-25 (IL-17E) receptor pathway in moderate to severe atopic dermatitis (AD). more info >> |
|
Tuesday, April 16, 2024 |
|
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy |
SinoMab BioScience announced preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy. more info >> |
|
Tuesday, September 12, 2023 |
|
SinoMab's IND Application of SM17 has once again Received Approval from NAMP |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, August 14, 2023 |
|
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, June 12, 2023 |
|
SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, May 22, 2023 |
|
SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, December 19, 2022 |
|
SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards" |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
Friday, November 4, 2022 |
|
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
Wednesday, August 24, 2022 |
|
Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
Friday, July 8, 2022 |
|
SinoMab Received the Highest Subsidy from HKSTP |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Xiaocaiyuan (00999.HK) Continues to Outperform The Market, Customer Traffic Up 21% YoY During National Day Golden Week
Oct 14, 2025 11:18 HKT/SGT
|
|
|
Former Premier of Queensland Takes Over Reins of Australian Battery Industry Association (AMBC) Cofounded by GMG's Managing Director
Oct 13, 2025 20:59 HKT/SGT
|
|
|
45th Autumn Electronics Fair and electronicAsia open today
Oct 13, 2025 20:14 HKT/SGT
|
|
|
Patriot Critical Minerals Confirms Largest Tungsten Resource in the United States with Filing of SEC S-K 1300 Technical Report
Oct 13, 2025 20:09 HKT/SGT
|
|
|
Kangji Medical and Knight Bidco Jointly Dispatch Scheme Document for Privatisation Proposal
Oct 13, 2025 10:14 HKT/SGT
|
|
|
Open Dialogue Project Launches 2026 International Essay Contest on Global Development
Oct 11, 2025 17:00 HKT/SGT
|
|
|
After Beijing, Shoucheng Holdings Opens Robot Experience Store in Chengdu's Core Business District, National Rollout Begins as Consumer-Facing Scenarios Accelerate
Oct 11, 2025 09:58 HKT/SGT
|
|
|
Scandium International Mining Announces Grant of New Mining Lease at Nyngan Scandium Project
Oct 11, 2025 02:29 HKT/SGT
|
|
|
Hitachi Advances Strategic Alliance with Google Cloud to Empower Frontline Workers with Field-Specific AI Agents
Oct 10, 2025 0:58 JST
|
|
|
Honda Issues Integrated Report - "Honda Report 2025"
Oct 10, 2025 0:46 JST
|
|
|
DENSO's Electrification Products Adopted for TOYOTA's New "bZ4X"
Oct 10, 2025 0:21 JST
|
|
|
Newly developed eAxle adopted for TOYOTA's new "bZ4X"
Oct 10, 2025 0:08 JST
|
|
|
MHIET and MHI-TC Complete Delivery of First "COORDY" Controller Providing Optimized Control of Multiple Power Sources
Oct 10, 2025 23:47 JST
|
|
|
Fujitsu migrates service operations virtualization platform used by 3,000 companies to Nutanix and introduces migration support services utilizing proven expertise
Oct 10, 2025 23:25 JST
|
|
|
Shares of Golden Leaf International Group Limited Commence Trading on GEM of HKEX Today
Oct 10, 2025 19:10 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|